Skip to content
Nonprofiteer
← DAVOS ALZHEIMERS COLLABORATIVE INC

Form 990 for tax year 2023

Filed by DAVOS ALZHEIMERS COLLABORATIVE INC.

Totals

Total revenue
$8,484,685
Total expenses
$9,009,933
Contributions and grants received
$8,484,685
Grants paid
$1,996,537
Program service revenue
$0
Investment income
$0
Other revenue
$0
Total assets, end of year
$14,067,138
Total liabilities, end of year
$1,186,024
Net assets or fund balances, end of year
$12,881,114
Program services expenses (Part IX)
$8,389,474
Management and general expenses
$602,834
Fundraising expenses
$17,625
Program service expenses (Part III)
$8,389,474

Program services were 93.1% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1f · All other contributions, gifts and grants

    $8,484,685

  • 1g · Noncash contributions included above

    $560,400

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $1,289,183 · program services $1,289,183

  • 3 · Grants to foreign organizations and individuals

    total $707,354 · program services $707,354

  • 11a · Fees: management

    total $911,000 · program services $627,200 · management and general $283,800

  • 11b · Fees: legal

    total $315,382 · program services $246,551 · management and general $68,244 · fundraising $587

  • 11c · Fees: accounting

    total $127,272 · program services $99,404 · management and general $27,630 · fundraising $238

  • 11g · Fees: other

    total $4,615,902 · program services $4,598,883 · management and general $16,841 · fundraising $178

  • 12 · Advertising and promotion

    total $636,629 · program services $560,656 · management and general $69,383 · fundraising $6,590

  • 13 · Office expenses

    total $1,577 · program services $1,013 · management and general $564

  • 14 · Information technology

    total $7,958 · program services $6,691 · management and general $1,256 · fundraising $11

  • 17 · Travel

    total $276,208 · program services $171,181 · management and general $105,027

  • 19 · Conferences, conventions and meetings

    total $106,134 · program services $71,134 · management and general $25,000 · fundraising $10,000

  • 23 · Insurance

    total $11,382 · program services $8,890 · management and general $2,471 · fundraising $21

  • 24a · Other expenses: SUBSCRIPTION FEES

    total $3,952 · program services $1,334 · management and general $2,618

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $14,926,469 · end of year $13,720,960

  • 3 · Pledges and grants receivable

    beginning of year $16,547 · end of year $100,000

  • 9 · Prepaid expenses and deferred charges

    beginning of year $52,929 · end of year $246,178

  • 17 · Accounts payable and accrued expenses

    beginning of year $1,586,998 · end of year $1,186,024

  • 27 · Net assets without donor restrictions

    beginning of year $12,756,730 · end of year $12,177,430

  • 28 · Net assets with donor restrictions

    beginning of year $652,217 · end of year $703,684

Mission and programs · 2023

Mission

DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND.

Activities or mission (Part I)

SEE PART III LINE 1.

  • HEALTHCARE SYSTEM PREPAREDNESS: DAC IS INVESTING TO TRANSFORM THE WAY HEALTHCARE SYSTEMS WORLDWIDE DETECT, DIAGNOSE AND TREAT ALZHEIMER'S. THE GOAL IS TO TAKE ADVANTAGE OF FUTURE INNOVATIONS TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE EVERYWHERE. IN 2023, DAC CONTINUED TO ADVANCE 7 FLAGSHIP PROJECTS IN 6 COUNTRIES AS WELL AS SUPPORT AND MONITOR THE EXECUTION OF THE INITIAL GRANTS PROGRAM (12 GRANTS IN TOTAL). ADDITIONALLY, DAC DESIGNED OUR NEXT SET OF FLAGSHIP PROJECTS AND HAS BEEN WORKING CLOSELY WITH SITES ACROSS THE GLOBE TO LAUNCH THE PROGRAM IN 2024.

    Expenses $6,227,466 · Grants $1,339,037

  • GLOBAL COHORTS - DAC IS BUILDING GLOBAL COHORTS TO ADVANCE UNDERSTANDING OF ALZHEIMER'S AMONG DIVERSE POPULATIONS. THIS DATA WILL PROVIDE THE FOUNDATION FOR IDENTIFYING NEW BIOMARKERS AND DEVELOPING TARGETED TREATMENTS THAT WORK FOR PEOPLE WORLDWIDE. IN 2023, DAC ADVANCED OUR RESEARCH AGENDA BY:- PROVIDING MULTI-YEAR FUNDING TO WORLDWIDE FINGERS TO ADAPT AND CUSTOMIZE THEIR RISK REDUCTION PROTOCOL IN OVER 60 COUNTRIES.- COMPLETING THE FIRST TWO PHASES OF A LONG-TERM PARTNERSHIP WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA THAT IS VALIDATING COGNITIVE TESTS, SALIVA BASED POLYGENIC RISK SCORES AND NOVEL DIGITAL COGNITIVE ASSESSMENTS IN LOCAL EAST AFRICAN POPULATION WITH THE GOAL OF CREATING A CLINICAL TRIAL READY COHORT FOR TESTING PHARMACOLOGICAL AND NON-PHARMACOLOGICAL INTERVENTIONS. - ACQUIRING BLOOD SAMPLES FROM FIRST 300 OF A 3000 PERSON HIGHLY CHARACTERIZED (PET, CLINICAL DX) SOUTH KOREAN COHORT AND ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR FURTHER ANALYSIS BY DAC'S NETWORK OF DIAGNOSTIC AND PHARMA PARTNERS TO GENERATE AD BLOOD BIOMARKER VALIDATION DATA.- BUILDING AND MAINTAINING A ROBUST PIPELINE OF COMMITTED COHORTS WITH DETAILED PROPOSALS MOUS, RANGING FROM COLOMBIA TO TANZANIA TO RURAL TEXAS, TO TEST AND VALIDATE EARLY COGNITIVE IMPAIRMENT DETECTION TECHNOLOGIES WITH A FOCUS ON REMOTE, UNDERSERVED AREAS TO FIND TOOLS THAT CAN MORE EASILY SCALE GLOBALLY.

    Expenses $2,017,227 · Grants $657,500

  • GLOBAL CLINICAL TRIALS - DAC IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED FOR ACCELERATING STUDIES AND IMPLEMENTING NOVEL TRIAL DESIGNS THAT IS BEING FUNDED BY A PHARMACEUTICAL COMPANY SPONSOR. DAC'S WORK THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM SHOULD BE ABLE TO PROVIDE CLINICAL TRIAL READY POPULATIONS IN 2024 AND CREATE MORE OPPORTUNITIES FOR THE GLOBAL CLINICAL TRIAL PROGRAM.

    Expenses $144,781

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • George Vradenburg

    CHAIR & PRESIDENT

    Total calculated
    $0
    Hours/week
    20 + 2 related

  • Andrew Holzapfel

    COO (SEE SCHEDULE O)

    Total calculated
    $0
    Hours/week
    30 + 3 related

  • Freda Lewis Hall

    TREASURER

    Total calculated
    $0
    Hours/week
    1 + 1 related

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.

Grants on this return

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

  • DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE)

    N/A · PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH. · SZ · controlled entity

    Directly controlled by DAC

Provenance

Return type
form_990
Tax year
2023
Filed
12 June 2024
IRS schema version
2023v5.0
Source object
202431649349300018

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.